An Exploratory Study to Evaluate Immune Restoration Following Removal of Viral Antigen in Treatment-Naïve and Treatment-Experienced Adults With Genotype (GT) 1a Chronic Hepatitis C Virus (HCV) Infection Administered Ombitasvir/ ABT-450/Ritonavir With Dasabuvir and Ribavirin (RBV) for 12 Weeks
Phase of Trial: Phase III
Latest Information Update: 08 Dec 2016
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Dasabuvir; Ribavirin
- Indications Hepatitis C
- Focus Pharmacodynamics
- Sponsors AbbVie
- 05 Dec 2016 Status changed from active, no longer recruiting to completed.
- 11 Apr 2016 Status changed from recruiting to active, no longer recruiting.
- 08 Feb 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016 as per ClinicalTrials.gov record.